A specific example is the use of CD40 agonists as costimulatory molecules to activate dendritic cells [Singh et al., 2022] which Yang et al. [2021] found to be synergistic models in combination with IL-6 targeting, prolonged survival and eradicated gliomas in preclinical models. The gene discussed is CD40; the disease is central nervous system cancer.